Go Pro
→ Nvidia's CEO says this small device is critical for AI growth (From Brownstone Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
$17.42
$17.42
$14.50
▼
$19.92
$424.04M1.1518,480 shsN/A
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
0.00%0.00%0.00%-3.97%-8.65%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
$17.42
$17.42
$14.50
▼
$19.92
$424.04M1.1518,480 shsN/A
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
0.00%0.00%0.00%-3.97%-8.65%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest TILS, AVCT, HZD, and PRTC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/18/2026
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D) ➝ Sell (D-)
(Data available from 8/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
$4.66M91.01N/AN/A$12.65 per share1.38
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
-$109.74MN/AN/AN/AN/AN/AN/AN/A8/27/2026 (Estimated)

Latest TILS, AVCT, HZD, and PRTC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/27/2026H1 2026
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
-$1.16N/AN/AN/A$24.80 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
N/A
6.59
6.59

Institutional Ownership

CompanyInstitutional Ownership
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
0.04%

Insider Ownership

CompanyInsider Ownership
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
5.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
10024.34 million23.05 millionNot Optionable

Recent News About These Companies

PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis ...
July 13, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/puretech-founded-entity-celea-therapeutics-060000287.html
PureTech Subsidiary Celea Begins Phase 3 IPF Study Comparing Deupirfenidone With Standard Therapy (PRTC)
July 13, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/puretech-subsidiary-celea-begins-phase-071627519.html
PureTech entity Celea raises $180 million to move lung disease drug into late stage trial
July 2, 2026  |  reuters.comhttps://www.reuters.com/legal/litigation/puretech-entity-celea-raises-180-million-move-lung-disease-drug-into-late-stage-2026-07-02/
PureTech Health plc American Depositary Shares (PRTC) Real-Time
July 1, 2026  |  nasdaq.comhttps://www.nasdaq.com/market-activity/stocks/prtc/real-time
2 UK shares tipped to more than double my money in 2026!
June 20, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/2-uk-shares-tipped-more-063100674.html
PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
June 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/puretech-founded-entity-seaport-therapeutics-060000179.html
PureTech to Showcase Deupirfenidone Program at the American Thoracic Society International Conference
May 13, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260513421721/en/puretech-to-showcase-deupirfenidone-program-at-the-american-thoracic-society-international-conference/
PureTech Health shares boosted as investee Seaport Therapeutics prices Nasdaq IPO
May 1, 2026  |  proactiveinvestors.co.ukhttps://www.proactiveinvestors.co.uk/companies/news/1091582?snapi
PureTech Announces Annual Results for Year Ended December 31, 2025
April 29, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260428142968/en/puretech-announces-annual-results-for-year-ended-december-31-2025/
PureTech Health: Notice of Results
April 13, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260412617965/en/puretech-health-notice-of-results/
PureTech Gains on Results
April 2, 2026  |  baystreet.cahttps://www.baystreet.ca/stockstowatch/23028/PureTech-Gains-on-Results
PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine
April 2, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260401875786/en/puretech-announces-publication-of-phase-2b-elevate-ipf-trial-results-in-the-american-journal-of-respiratory-and-critical-care-medicine/
PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans
March 25, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260325523679/en/puretech-founded-entity-seaport-therapeutics-announces-publication-in-science-translational-medicine-featuring-glyphallo%e2%84%a2-spt-300-as-the-first-triglyceride-mimetic-prodrug-to-achieve-therapeutically-relevant-drug-levels-in-humans/
PureTech to Present at the Leerink Partners Global Healthcare Conference
February 25, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260224469853/en/puretech-to-present-at-the-leerink-partners-global-healthcare-conference/
PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
February 19, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260219184180/en/puretech-announces-orphan-drug-designations-granted-by-the-u.s.-food-and-drug-administration-and-european-commission-for-deupirfenidone-lyt-100-in-idiopathic-pulmonary-fibrosis/
PureTech Health plc (PRTC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
January 14, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4859997-puretech-health-plc-prtc-presents-at-44th-annual-j-p-morgan-healthcare-conference-transcript
PureTech to Present at 44th Annual J.P. Morgan Healthcare Conference
January 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/puretech-present-44th-annual-j-120000136.html
PureTech CEO to present at JP Morgan Healthcare Conference
January 6, 2026  |  msn.comhttps://www.msn.com/en-us/money/companies/puretech-ceo-to-present-at-jp-morgan-healthcare-conference/ar-AA1TG9jD
PureTech Health plc (LON:PRTC) is favoured by institutional owners who hold 73% of the company
January 3, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/puretech-health-plc-lon-prtc-091834606.html
PureTech Appoints Robert Lyne as Chief Executive Officer
December 18, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20251217152848/en/puretech-appoints-robert-lyne-as-chief-executive-officer/

Media Sentiment Over Time

PureTech Health stock logo

PureTech Health NASDAQ:PRTC

$17.42 0.00 (0.00%)
As of 07/31/2026

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas